Review

primary hrpe cells (ScienCell)

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

ScienCell primary hrpe cells

DEL-1 ameliorates ER stress in <t>hRPE</t> <t>cells.</t> A Western blot analysis depicting phosphorylated eIF2α and CHOP in hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. B Western blot analysis depicting phosphorylated eIF2α and CHOP in hRPE cells treated with DEL-1 (0–2 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin treatment

Primary Hrpe Cells, supplied by ScienCell, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/primary+hrpe+cells/pmc10775473-40-3-7?v=ScienCell
Average 90 stars, based on 1 article reviews

primary hrpe cells - by Bioz Stars, 2026-07

90/100 stars

Images

1) Product Images from "DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells"

Article Title: DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells

Journal: Journal of Translational Medicine

doi: 10.1186/s12967-024-04858-9

DEL-1 ameliorates ER stress in hRPE cells. A Western blot analysis depicting phosphorylated eIF2α and CHOP in hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. B Western blot analysis depicting phosphorylated eIF2α and CHOP in hRPE cells treated with DEL-1 (0–2 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin treatment

Figure Legend Snippet: DEL-1 ameliorates ER stress in hRPE cells. A Western blot analysis depicting phosphorylated eIF2α and CHOP in hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. B Western blot analysis depicting phosphorylated eIF2α and CHOP in hRPE cells treated with DEL-1 (0–2 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin treatment

Techniques Used: Western Blot, In Vitro, Control

DEL-1 mitigates ER stress-induced VEGF expression and apoptosis in hRPE cells. A Cell viability assay in hRPE cells treated with tunicamycin (0–2 μg/mL) or DEL-1 (0–2 μg/mL) for 24 h. B Western blot analysis of VEGF in hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. C Cell viability and caspase 3 activity assay in hRPE cells treated with tunicamycin (2 μg/mL) and/or DEL-1 (0–5 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment

Figure Legend Snippet: DEL-1 mitigates ER stress-induced VEGF expression and apoptosis in hRPE cells. A Cell viability assay in hRPE cells treated with tunicamycin (0–2 μg/mL) or DEL-1 (0–2 μg/mL) for 24 h. B Western blot analysis of VEGF in hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. C Cell viability and caspase 3 activity assay in hRPE cells treated with tunicamycin (2 μg/mL) and/or DEL-1 (0–5 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment

Techniques Used: Expressing, Viability Assay, Western Blot, Caspase-3 Activity Assay, In Vitro, Control

Involvement of AMPK in the effects of DEL-1 on ER stress, VEGF expression, and apoptosis in hRPE cells. A Western blot analysis of phosphorylated AMPK, CAMKK2 and LKB1 in hRPE cells treated with DEL-1 (0–1 μg/mL) for 24 h. B Western blot analysis of phosphorylated eIF2α, CHOP, and VEGF in AMPK siRNA-transfected hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (1 μg/mL) for 24 h. C Cell viability and caspase 3 activity assay in AMPK siRNA-transfected hRPE cells treated with tunicamycin (2 μg/mL) and/or DEL-1 (1 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment. # P < 0.05 compared with tunicamycin (1 or 2 μg/mL) and DEL-1 treatment

Figure Legend Snippet: Involvement of AMPK in the effects of DEL-1 on ER stress, VEGF expression, and apoptosis in hRPE cells. A Western blot analysis of phosphorylated AMPK, CAMKK2 and LKB1 in hRPE cells treated with DEL-1 (0–1 μg/mL) for 24 h. B Western blot analysis of phosphorylated eIF2α, CHOP, and VEGF in AMPK siRNA-transfected hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (1 μg/mL) for 24 h. C Cell viability and caspase 3 activity assay in AMPK siRNA-transfected hRPE cells treated with tunicamycin (2 μg/mL) and/or DEL-1 (1 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment. # P < 0.05 compared with tunicamycin (1 or 2 μg/mL) and DEL-1 treatment

Techniques Used: Expressing, Western Blot, Transfection, Caspase-3 Activity Assay, In Vitro, Control

Autophagy-mediated signaling contributes to the protective effects of DEL-1 against ER stress-induced VEGF expression and injury in hRPE cells. A MDC staining and Western blot analysis of LC3 I/II and p62 in hRPE cells treated with DEL-1 (0–1 μg/mL) for 24 h. B Western blot analysis of phosphorylated eIF2α, CHOP, and VEGF in hRPE cells treated with tunicamycin (1 μg/mL), DEL-1 (1 μg/mL), and/or 3-MA (2 mM) for 24 h. C Cell viability and caspase 3 activity assay in hRPE cells treated with tunicamycin (1 μg/mL), DEL-1 (1 μg/mL), and/or 3-MA (2 mM) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment. # P < 0.05 compared with tunicamycin (1 or 2 μg/mL) and DEL-1 treatment

Figure Legend Snippet: Autophagy-mediated signaling contributes to the protective effects of DEL-1 against ER stress-induced VEGF expression and injury in hRPE cells. A MDC staining and Western blot analysis of LC3 I/II and p62 in hRPE cells treated with DEL-1 (0–1 μg/mL) for 24 h. B Western blot analysis of phosphorylated eIF2α, CHOP, and VEGF in hRPE cells treated with tunicamycin (1 μg/mL), DEL-1 (1 μg/mL), and/or 3-MA (2 mM) for 24 h. C Cell viability and caspase 3 activity assay in hRPE cells treated with tunicamycin (1 μg/mL), DEL-1 (1 μg/mL), and/or 3-MA (2 mM) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment. # P < 0.05 compared with tunicamycin (1 or 2 μg/mL) and DEL-1 treatment

Techniques Used: Expressing, Staining, Western Blot, Caspase-3 Activity Assay, In Vitro, Control

DEL-1 attenuates ER stress and apoptosis in primary hRPE cells. A Western blot analysis depicting phosphorylated eIF2α and CHOP in primary hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. B Cell viability and caspase 3 activity assay in primary hRPE cells treated with tunicamycin (2 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment

Figure Legend Snippet: DEL-1 attenuates ER stress and apoptosis in primary hRPE cells. A Western blot analysis depicting phosphorylated eIF2α and CHOP in primary hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. B Cell viability and caspase 3 activity assay in primary hRPE cells treated with tunicamycin (2 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment

Techniques Used: Western Blot, Caspase-3 Activity Assay, In Vitro, Control

Figure Legend Snippet: Illustration depicting the effects of the myokine DEL-1 on VEGF expression and apoptosis in hRPE cells

Techniques Used: Expressing

Image Search Results

(A) hRPE cells were treated with 200 µg/ml for 24 and 48 hr in the absence or presence of PMC (1.3 µM). Cytotoxicity was also measured in untreated (control) and PMC alone treated cells. Cell death was measured in the condition media using the LDH assay, n=3. Values are expressed as mean ± SEM. Statistical analysis was conducted using one-way ANOVA, ***P<0.001, n=3. Heatmap of top differently expressed genes of bulk RNA sequencing in (B) apoptosis and (c) antioxidant pathways, n=3. Colors shows intensity in z-scored units where red shows replicates with high expression (z-score= +5) and blue shows replicates with low expression (z-score =-5).

Journal: bioRxiv

Article Title: Mechanism of PMC (2,2,5,7,8-pentamethyl-6-chromanol), a sterically hindered phenol antioxidant, in rescuing oxidized low-density lipoprotein-induced cytotoxicity in human retinal pigment epithelial cells

doi: 10.1101/2025.06.19.660627

Figure Lengend Snippet: (A) hRPE cells were treated with 200 µg/ml for 24 and 48 hr in the absence or presence of PMC (1.3 µM). Cytotoxicity was also measured in untreated (control) and PMC alone treated cells. Cell death was measured in the condition media using the LDH assay, n=3. Values are expressed as mean ± SEM. Statistical analysis was conducted using one-way ANOVA, ***P<0.001, n=3. Heatmap of top differently expressed genes of bulk RNA sequencing in (B) apoptosis and (c) antioxidant pathways, n=3. Colors shows intensity in z-scored units where red shows replicates with high expression (z-score= +5) and blue shows replicates with low expression (z-score =-5).

Article Snippet: Primary human fetal retinal pigmented epithelium cells (hRPE) (Lonza, USA) were cultured in 50% (v/v) DMEM/F12 (Life Technologies, USA)/50% (v/v) αMEM (Sigma-Aldrich, USA) supplemented with 1x penicillin-streptomycin, Glutamax, sodium pyruvate, non-essential amino acids (all from Life Technologies, USA).

Techniques: Control, Lactate Dehydrogenase Assay, RNA Sequencing, Expressing

(A) hRPE cells matured for 4 weeks, were treated with ox-LDL (200 µg/ml) with or without the presence of PMC (1.3 µM) in serum-free media. Relative HMOX1 transcript levels were measured using qPCR. (B) Western blotting of the hRPE cells with the above indicated treatments at 24 and 48 hr was conducted to examine HO-1 levels. (C) Quantification was performed using densitometry after normalization with GAPDH, n=3. (D) HMOX-1 mRNA levels were determined by PCR in serum-starved ARPE-19 cells treated with ox-LDL in the presence or absence of PMC and qPCR. (E) Cell lysates from ARPE-19 cells treated as above-were examined using western blot to determined HO-1 levels. (F) Quantification of HO-1 levels were conducted after normalization with α -tubulin. HMOX1/HO-1 was also assessed in hRPE and ARPE-19 cells treated with PMC alone. Serum-starved untreated cells were considered as control for all the experiments. Values are indicated as mean ± SEM of n=3. One-way ANOVA was used for statistical analysis, *P<0.05, **P<0.01, ***P<0.001

Journal: bioRxiv

doi: 10.1101/2025.06.19.660627

Figure Lengend Snippet: (A) hRPE cells matured for 4 weeks, were treated with ox-LDL (200 µg/ml) with or without the presence of PMC (1.3 µM) in serum-free media. Relative HMOX1 transcript levels were measured using qPCR. (B) Western blotting of the hRPE cells with the above indicated treatments at 24 and 48 hr was conducted to examine HO-1 levels. (C) Quantification was performed using densitometry after normalization with GAPDH, n=3. (D) HMOX-1 mRNA levels were determined by PCR in serum-starved ARPE-19 cells treated with ox-LDL in the presence or absence of PMC and qPCR. (E) Cell lysates from ARPE-19 cells treated as above-were examined using western blot to determined HO-1 levels. (F) Quantification of HO-1 levels were conducted after normalization with α -tubulin. HMOX1/HO-1 was also assessed in hRPE and ARPE-19 cells treated with PMC alone. Serum-starved untreated cells were considered as control for all the experiments. Values are indicated as mean ± SEM of n=3. One-way ANOVA was used for statistical analysis, *P<0.05, **P<0.01, ***P<0.001

Techniques: Western Blot, Control

(A) Serum-starved hRPE cells were treated with ox-LDL (200 µg/ml) in the presence or absence of PMC (1.3 µM). NQO1 levels were determined using qPCR at 24 and 48 hr, n=6. (B) Western blot was conducted on cell lysates from hRPE cells treated with ox-LDL with or without PMC to determine NQO1 levels. (C) Densitometry was conducted with normalization for GAPDH, n=3. (D) Serum-starved ARPE-19 treated under the same experimental treatment conditions as above were analyzed for NQO1 levels using qPCR, n=6. (E) NQO1 protein levels were measured in cell lysates from ARPE-19 in the ox-LDL treated groups with or without PMC. (F) Densitometry analysis was conducted with normalization with GAPDH to quantify NQO1 levels, n=3. NQO1 levels were also measured in hRPE and ARPE-19 cells treated with PMC alone. Serum-starved untreated cells were considered as the control for all the experiments. Values are indicated as mean ± SEM of the indicated n. One-way ANOVA was used for statistical analysis, *P<0.05, **P<0.01, ***P<0.001

Journal: bioRxiv

doi: 10.1101/2025.06.19.660627

Figure Lengend Snippet: (A) Serum-starved hRPE cells were treated with ox-LDL (200 µg/ml) in the presence or absence of PMC (1.3 µM). NQO1 levels were determined using qPCR at 24 and 48 hr, n=6. (B) Western blot was conducted on cell lysates from hRPE cells treated with ox-LDL with or without PMC to determine NQO1 levels. (C) Densitometry was conducted with normalization for GAPDH, n=3. (D) Serum-starved ARPE-19 treated under the same experimental treatment conditions as above were analyzed for NQO1 levels using qPCR, n=6. (E) NQO1 protein levels were measured in cell lysates from ARPE-19 in the ox-LDL treated groups with or without PMC. (F) Densitometry analysis was conducted with normalization with GAPDH to quantify NQO1 levels, n=3. NQO1 levels were also measured in hRPE and ARPE-19 cells treated with PMC alone. Serum-starved untreated cells were considered as the control for all the experiments. Values are indicated as mean ± SEM of the indicated n. One-way ANOVA was used for statistical analysis, *P<0.05, **P<0.01, ***P<0.001

Techniques: Western Blot, Control

(A) Illustration showing the timeline of 48 hr siHMOX1 silencing and 24 hr ox-LDL treatments in the presence or absence of PMC in hRPE cells. (B) Western blotting was conducted to estimate HO-1 levels in hRPE cells subjected to siScr or siHMOX1 for 48 hr followed by ox-LDL (200 µg/ml) treatments with or without PMC (1.3 µM). (C) Quantification of HO-1 levels was performed using densitometry after normalization with GAPDH, n=3. (D) LDH levels were measured in the conditioned media from siScr or siHMOX-treated cells along with the siScr and siHMOX1 cells that were treated with ox-LDL with or without PMC, n=14. (E) Illustration of the timeline indicating, 48 hr siHMOX1 silencing in hRPE cells followed by additional 48 hr treatment of ox-LDL with/without PMC. (F) HO-1 levels were detected in hRPE cells treated with siScr or siHMOX1 for 48 hr, followed by ox-LDL in the presence or absence of PMC using western blotting. (G) Densitometry analysis was conducted to quantify HO-1 levels after normalization with GAPDH, n=3. (H) Cytotoxicity was analyzed by assaying LDH in the conditioned media of siScr and siHMOX1 and siScr and siHMOX cells that were subjected to ox-LDL with/without PMC treatment, n=6. Cells treated with ox-LDL in the presence or absence of PMC without siScr or siHMOX1 were used as control for both 24 hr and 48 hr ox-LDL and ox-LDL with PMC treatments, n=6. Values are indicated as mean ± SEM of the indicated n. One-way ANOVA was used for statistical analysis, *P<0.05, **P<0.01, ***P<0.001

Journal: bioRxiv

doi: 10.1101/2025.06.19.660627

Figure Lengend Snippet: (A) Illustration showing the timeline of 48 hr siHMOX1 silencing and 24 hr ox-LDL treatments in the presence or absence of PMC in hRPE cells. (B) Western blotting was conducted to estimate HO-1 levels in hRPE cells subjected to siScr or siHMOX1 for 48 hr followed by ox-LDL (200 µg/ml) treatments with or without PMC (1.3 µM). (C) Quantification of HO-1 levels was performed using densitometry after normalization with GAPDH, n=3. (D) LDH levels were measured in the conditioned media from siScr or siHMOX-treated cells along with the siScr and siHMOX1 cells that were treated with ox-LDL with or without PMC, n=14. (E) Illustration of the timeline indicating, 48 hr siHMOX1 silencing in hRPE cells followed by additional 48 hr treatment of ox-LDL with/without PMC. (F) HO-1 levels were detected in hRPE cells treated with siScr or siHMOX1 for 48 hr, followed by ox-LDL in the presence or absence of PMC using western blotting. (G) Densitometry analysis was conducted to quantify HO-1 levels after normalization with GAPDH, n=3. (H) Cytotoxicity was analyzed by assaying LDH in the conditioned media of siScr and siHMOX1 and siScr and siHMOX cells that were subjected to ox-LDL with/without PMC treatment, n=6. Cells treated with ox-LDL in the presence or absence of PMC without siScr or siHMOX1 were used as control for both 24 hr and 48 hr ox-LDL and ox-LDL with PMC treatments, n=6. Values are indicated as mean ± SEM of the indicated n. One-way ANOVA was used for statistical analysis, *P<0.05, **P<0.01, ***P<0.001

Techniques: Western Blot, Control

Continuous PMC presence is required for protection against ox-LDL. (A) Serum-starved hRPE cells were treated with either ox-LDL (200 µg/ml) and PMC (1.3 µM) alone or, ox-LDL and PMC under different treatment conditions. ox-LDL+PMC denotes simultaneous treatment, while in other treatment groups either the cells were pretreated with PMC or with ox-LDL. Following these treatments, media were replaced with ox-LDL+PMC, ox-LDL alone, or PMC alone. In another group, media were not replaced, and treatments were added to the same media. Cells were pretreated with PMC and ox-LDL was added to the same media or pretreated with ox-LDL and an approximately 10-fold higher PMC concentration (10 µM) was added to the same media. Untreated cells were considered as controls. Values are indicated as mean ± SEM of n=3. One-way ANOVA was used for statistical analysis, ***P<0.001. (B) Graphical summary of the PMC mediated protection against ox-LDL in RPE. Uptake of ox-LDL via the CD36 receptor causes lysosomal destabilization and oxidative stress in RPE leading to ROS generation. This triggers Nrf2 dissociation from Keap1 and its translocation to the nucleus where it interacts with the specific promoter region, ARE, leading to the upregulation of HMOX1 and NQO1. PMC prevents this upregulation of HMOX1/HO-1 and NQO1 levels by preventing ROS generation. Created using BioRender.

Journal: bioRxiv

doi: 10.1101/2025.06.19.660627

Figure Lengend Snippet: Continuous PMC presence is required for protection against ox-LDL. (A) Serum-starved hRPE cells were treated with either ox-LDL (200 µg/ml) and PMC (1.3 µM) alone or, ox-LDL and PMC under different treatment conditions. ox-LDL+PMC denotes simultaneous treatment, while in other treatment groups either the cells were pretreated with PMC or with ox-LDL. Following these treatments, media were replaced with ox-LDL+PMC, ox-LDL alone, or PMC alone. In another group, media were not replaced, and treatments were added to the same media. Cells were pretreated with PMC and ox-LDL was added to the same media or pretreated with ox-LDL and an approximately 10-fold higher PMC concentration (10 µM) was added to the same media. Untreated cells were considered as controls. Values are indicated as mean ± SEM of n=3. One-way ANOVA was used for statistical analysis, ***P<0.001. (B) Graphical summary of the PMC mediated protection against ox-LDL in RPE. Uptake of ox-LDL via the CD36 receptor causes lysosomal destabilization and oxidative stress in RPE leading to ROS generation. This triggers Nrf2 dissociation from Keap1 and its translocation to the nucleus where it interacts with the specific promoter region, ARE, leading to the upregulation of HMOX1 and NQO1. PMC prevents this upregulation of HMOX1/HO-1 and NQO1 levels by preventing ROS generation. Created using BioRender.

Techniques: Concentration Assay, Translocation Assay

Journal: Journal of Translational Medicine

Article Title: DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells

doi: 10.1186/s12967-024-04858-9

Figure Lengend Snippet: DEL-1 ameliorates ER stress in hRPE cells. A Western blot analysis depicting phosphorylated eIF2α and CHOP in hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. B Western blot analysis depicting phosphorylated eIF2α and CHOP in hRPE cells treated with DEL-1 (0–2 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin treatment

Article Snippet: Cultivation of primary hRPE cells obtained from Sciencell Research Laboratories (San Diego, CA, USA) was performed using optimized Epithelial Cell Medium (Sciencell Research Laboratories).

Techniques: Western Blot, In Vitro, Control

Journal: Journal of Translational Medicine

Article Title: DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells

doi: 10.1186/s12967-024-04858-9

Figure Lengend Snippet: DEL-1 mitigates ER stress-induced VEGF expression and apoptosis in hRPE cells. A Cell viability assay in hRPE cells treated with tunicamycin (0–2 μg/mL) or DEL-1 (0–2 μg/mL) for 24 h. B Western blot analysis of VEGF in hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. C Cell viability and caspase 3 activity assay in hRPE cells treated with tunicamycin (2 μg/mL) and/or DEL-1 (0–5 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment

Techniques: Expressing, Viability Assay, Western Blot, Caspase-3 Activity Assay, In Vitro, Control

Journal: Journal of Translational Medicine

Article Title: DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells

doi: 10.1186/s12967-024-04858-9

Figure Lengend Snippet: Involvement of AMPK in the effects of DEL-1 on ER stress, VEGF expression, and apoptosis in hRPE cells. A Western blot analysis of phosphorylated AMPK, CAMKK2 and LKB1 in hRPE cells treated with DEL-1 (0–1 μg/mL) for 24 h. B Western blot analysis of phosphorylated eIF2α, CHOP, and VEGF in AMPK siRNA-transfected hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (1 μg/mL) for 24 h. C Cell viability and caspase 3 activity assay in AMPK siRNA-transfected hRPE cells treated with tunicamycin (2 μg/mL) and/or DEL-1 (1 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment. # P < 0.05 compared with tunicamycin (1 or 2 μg/mL) and DEL-1 treatment

Techniques: Expressing, Western Blot, Transfection, Caspase-3 Activity Assay, In Vitro, Control

Journal: Journal of Translational Medicine

Article Title: DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells

doi: 10.1186/s12967-024-04858-9

Figure Lengend Snippet: Autophagy-mediated signaling contributes to the protective effects of DEL-1 against ER stress-induced VEGF expression and injury in hRPE cells. A MDC staining and Western blot analysis of LC3 I/II and p62 in hRPE cells treated with DEL-1 (0–1 μg/mL) for 24 h. B Western blot analysis of phosphorylated eIF2α, CHOP, and VEGF in hRPE cells treated with tunicamycin (1 μg/mL), DEL-1 (1 μg/mL), and/or 3-MA (2 mM) for 24 h. C Cell viability and caspase 3 activity assay in hRPE cells treated with tunicamycin (1 μg/mL), DEL-1 (1 μg/mL), and/or 3-MA (2 mM) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment. # P < 0.05 compared with tunicamycin (1 or 2 μg/mL) and DEL-1 treatment

Techniques: Expressing, Staining, Western Blot, Caspase-3 Activity Assay, In Vitro, Control

Journal: Journal of Translational Medicine

Article Title: DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells

doi: 10.1186/s12967-024-04858-9

Figure Lengend Snippet: DEL-1 attenuates ER stress and apoptosis in primary hRPE cells. A Western blot analysis depicting phosphorylated eIF2α and CHOP in primary hRPE cells treated with tunicamycin (1 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. B Cell viability and caspase 3 activity assay in primary hRPE cells treated with tunicamycin (2 μg/mL) and/or DEL-1 (0–1 μg/mL) for 24 h. Means ± SDs were calculated from three independent experiments in in vitro models. * P < 0.05 compared with the control. ! P < 0.05 compared with tunicamycin (1 or 2 μg/mL) treatment

Techniques: Western Blot, Caspase-3 Activity Assay, In Vitro, Control

Journal: Journal of Translational Medicine

Article Title: DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells

doi: 10.1186/s12967-024-04858-9

Figure Lengend Snippet: Illustration depicting the effects of the myokine DEL-1 on VEGF expression and apoptosis in hRPE cells

Techniques: Expressing

Dram2 loss exacerbates toxicity-induced human RPE cell death in vitro (A) Experimental design of loss of DRAM2 experiments in human cells. hRPE, human primary retinal pigment epithelial (RPE) cells; KD, knockdown; A2E, N-retinylidene-N-retinylethanolamine; NaOI 3 , Sodium Iodate; hPSC, human pluripotent stem cells; KO, Knockout. (B) Representative image of hRPE after infection with lentivirus expressing DRAM2 shRNA and GFP (left) and knockdown efficiency of the two different DRAM2 shRNAs assessed by quantitative RT-PCR (qPCR) analysis of DRAM2 expression (right) (C) hRPE cell survival following treatment with A2E (30 μM; left) and NaIO 3 (5 mM; right). Dotted horizontal line marks the median survival (50% of the cells alive). (D) Differentiation of DRAM2 WT and KO human pluripotent stem cells (hPSCs) into RPE (hPSC-RPE) showing pigmentation (top row, BF: Bright Field) and expression of RPE maker ZO-1 (bottom row). Scale bars: 50 µm. (E) Representative immunofluorescent image (left) of RPE marker ZO-1 (green) in hPSC-RPE DRAM2 WT, KO1, and KO2 and phagocytosis of FITC-labeled Photoreceptor Outer Segments (POS; red). Scale bar: 20 µm. Phagocytosis capacity of the cells was assessed by quantification of cells with internalized FITC-POS by flow cytometry ( DRAM2 WT: blue line, DRAM2 KO1 and 2: orange lines). (F) hPSC-RPE cell survival following treatment with A2E (30 μM; left) and NaIO 3 (5 mM; right). Dotted horizontal line marks the median survival.

Journal: Frontiers in Cell and Developmental Biology

Article Title: Integration of human stem cell-derived in vitro systems and mouse preclinical models identifies complex pathophysiologic mechanisms in retinal dystrophy

doi: 10.3389/fcell.2023.1252547

Figure Lengend Snippet: Dram2 loss exacerbates toxicity-induced human RPE cell death in vitro (A) Experimental design of loss of DRAM2 experiments in human cells. hRPE, human primary retinal pigment epithelial (RPE) cells; KD, knockdown; A2E, N-retinylidene-N-retinylethanolamine; NaOI 3 , Sodium Iodate; hPSC, human pluripotent stem cells; KO, Knockout. (B) Representative image of hRPE after infection with lentivirus expressing DRAM2 shRNA and GFP (left) and knockdown efficiency of the two different DRAM2 shRNAs assessed by quantitative RT-PCR (qPCR) analysis of DRAM2 expression (right) (C) hRPE cell survival following treatment with A2E (30 μM; left) and NaIO 3 (5 mM; right). Dotted horizontal line marks the median survival (50% of the cells alive). (D) Differentiation of DRAM2 WT and KO human pluripotent stem cells (hPSCs) into RPE (hPSC-RPE) showing pigmentation (top row, BF: Bright Field) and expression of RPE maker ZO-1 (bottom row). Scale bars: 50 µm. (E) Representative immunofluorescent image (left) of RPE marker ZO-1 (green) in hPSC-RPE DRAM2 WT, KO1, and KO2 and phagocytosis of FITC-labeled Photoreceptor Outer Segments (POS; red). Scale bar: 20 µm. Phagocytosis capacity of the cells was assessed by quantification of cells with internalized FITC-POS by flow cytometry ( DRAM2 WT: blue line, DRAM2 KO1 and 2: orange lines). (F) hPSC-RPE cell survival following treatment with A2E (30 μM; left) and NaIO 3 (5 mM; right). Dotted horizontal line marks the median survival.

Article Snippet: Human primary retinal pigment epithelial (hRPE) cells (Lonza #00194987) were maintained in Retinal Pigment Epithelial Cell Growth Medium (RtEGM; Lonza) per manufacturer protocols.

Techniques: In Vitro, Knock-Out, Infection, Expressing, shRNA, Quantitative RT-PCR, Marker, Labeling, Flow Cytometry

Increases in cell death rate and ROS generation in ARPE-19 cells and human RPE (hRPE) cells with or without BL exposure. (a) BL exposure increased the cell death rate and (b) ROS generation in ARPE-19 cells exposed to BL in a time-dependent manner. (c) ROS reactivity in ARPE-19 cells was significantly higher with BL exposure than without BL exposure 24 h later. (d) BL exposure increased the cell death rate and (e) ROS generation in hRPE cells exposed to BL. (f) ROS reactivity in hRPE cells was significantly higher with BL exposure than without BL exposure 24 h later. ∗ P < 0.05; ∗∗ P < 0.01.

Journal: Oxidative Medicine and Cellular Longevity

Article Title: Nuclear Factor (Erythroid-Derived)-Related Factor 2-Associated Retinal Pigment Epithelial Cell Protection under Blue Light-Induced Oxidative Stress

doi: 10.1155/2016/8694641

Figure Lengend Snippet: Increases in cell death rate and ROS generation in ARPE-19 cells and human RPE (hRPE) cells with or without BL exposure. (a) BL exposure increased the cell death rate and (b) ROS generation in ARPE-19 cells exposed to BL in a time-dependent manner. (c) ROS reactivity in ARPE-19 cells was significantly higher with BL exposure than without BL exposure 24 h later. (d) BL exposure increased the cell death rate and (e) ROS generation in hRPE cells exposed to BL. (f) ROS reactivity in hRPE cells was significantly higher with BL exposure than without BL exposure 24 h later. ∗ P < 0.05; ∗∗ P < 0.01.

Article Snippet: ARPE-19, a human RPE cell line, was purchased from the American Type Culture Collection (Rockville, MD, USA), and primary human RPE (hRPE) cell line was purchased from Lonza (Walkersville, MD, USA).

Techniques:

Review

Structured Review

Images

1) Product Images from "DEL-1: a promising treatment for AMD-associated ER stress in retinal pigment epithelial cells"

Similar Products

Image Search Results